Payment overview · 2025
General Payments
$1,094.47
37 reported records · 15 companies
Healthcare provider profile · identity verified
Ginger Lynne Irvin, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · COLUMBIA, SC · NPI 1023217908
Verified facts
What the public records show
CMS Open Payments records show Ginger Lynne Irvin, M.D. received $1,094.47 in general payments during 2025 across 37 reported records.
Cook Medical LLC accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cook Medical LLC | Unresolved — no canonical attribution shown | $316.35 | 28.9% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $245.58 | 22.4% | 2 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $194.57 | 17.8% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $119.99 | 11.0% | 2 | 2025 |
| Hydrofera LLC | Unresolved — no canonical attribution shown | $43.97 | 4.0% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $22.79 | 2.1% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $22.10 | 2.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.35 | 1.9% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $20.16 | 1.8% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $16.86 | 1.5% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $15.12 | 1.4% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $14.97 | 1.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $14.20 | 1.3% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $13.81 | 1.3% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $13.65 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,094.47 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS Normalized: strattice reconstructive tissue matrix bps |
Device | ABBVIE INC. | $245.58 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $194.57 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $194.57 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $109.20 | 8 | 2025 |
Source payment records
|
|||||
| GORE TAG Thoracic Branch Endoprosthesis Normalized: gore tag thoracic branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $104.08 | 1 | 2025 |
Source payment records
|
|||||
| COOK CELECT Normalized: cook celect |
Device | Cook Medical LLC | $89.41 | 1 | 2025 |
Source payment records
|
|||||
| COOK Normalized: cook |
Device | Cook Medical LLC | $87.79 | 8 | 2025 |
Source payment records
|
|||||
| CUTIMED SORBACT Normalized: cutimed sorbact |
Device | Hydrofera LLC | $43.97 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 5F VCS Normalized: cardiva vascade 5f vcs |
Device | CARDIVA MEDICAL, INC. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| R2P MISAGO Normalized: r2p misago |
Device | Terumo Medical Corporation | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| GORE PROPATEN Vascular Graft Normalized: gore propaten vascular graft |
Device | W. L. Gore & Associates, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH ALPHA Normalized: zenith alpha |
Device | Cook Medical LLC | $15.05 | 2 | 2025 |
Source payment records
|
|||||
| QUIKCLOT Normalized: quikclot |
Device | Teleflex LLC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| EVARREST Normalized: evarrest |
Biological | Ethicon US, LLC | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| PROLENE Normalized: prolene |
Device | Ethicon US, LLC | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO Normalized: v a c veraflo |
Device | Solventum Corporation | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| ROSEN Normalized: rosen |
Device | Cook Medical LLC | $8.52 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $6.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,094.47 · 37 records | Cook Medical LLC | ANGIO-SEAL, AZUR CX DETACHABLE, CARDIVA VASCADE 5F VCS, COLLAGENASE SANTYL, COOK, COOK CELECT, CUTIMED SORBACT, ENDOCROSS Device, ENROUTE Transcarotid Stent, EVARREST, GORE PROPATEN Vascular Graft, GORE TAG Thoracic Branch Endoprosthesis, Integra, Integra Dermal Regeneration Template, LYMPHA PRESS OPTIMAL PLUS(US) BT, METACROSS OTW, PCD-51 731A (US) - White, PCD-52 737A (US) White, PRIMATRIX, PRODIGY CATHETER, PROLENE, QUIKCLOT, R2P MISAGO, ROSEN, STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS, Torus Stent Graft System, V.A.C. VERAFLO, ZENITH ALPHA, ZENITH SPIRAL-Z, ZILVER PTX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error